gabexate has been researched along with Raynaud Disease in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Raynaud Disease: An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyazaki, S | 1 |
| Miura, K | 1 |
| Kasai, Y | 1 |
| Abe, K | 1 |
| Yoshinaga, K | 1 |
1 other study available for gabexate and Raynaud Disease
| Article | Year |
|---|---|
Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Adult; Aprotinin; Captopril; Female; Fingers; Gabexate; Gua | 1982 |